A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MSC-1 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 21 Nov 2018
At a glance
- Drugs MSC 1 (Primary)
- Indications Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Northern Biologics
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 14 May 2018 Status changed from not yet recruiting to recruiting.
- 06 Apr 2018 Status changed from planning to not yet recruiting.